Duality BiotherapeuticsĀ (9606 HK): Core Product Pipeline Is Progressing; Share Buyback Announced
āDuality Bio is advancing core products towards commercialization, but faces competition for market adoption. Amid multiple catalysts in 2026 for...
134 Views
Immuno-Oncology Drugs in Adjuvant Lung:Ā The Next Frontier in Strengthening Moats
The potential for Merck and Roche looks underappreciated.Innovation in immuno-oncology drugs has supported the moats for Merck & Co Inc. (MRK...
614 Views
Best Ideas List for January 2019
The Best Ideas list is a compilation of stock ideas sourced from Morningstarās global equity research team. With more than 100 analysts covering...
935 Views
The Case for Semi-Annual Reporting
Generally speaking, if Stanley Druckenmiller says something is a bad thing and Donald Trump suggests it is a good thing, or at least is an idea...
411 Views
Liquid Universe of European Ordinary and Preferred Shares: May '26 Report
European dual-class spreads tightened again in May as liquidity-driven convergence resumed. Handelsbanken, MFE and Telecom Italia led compression,...
109 Views